{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:17:59Z","timestamp":1791865079004,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jgar.2019.07.017","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T19:41:58Z","timestamp":1563997318000},"page":"209-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Activity of ceftolozane\u2013tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata \u2013 SMART United States 2016\u20132017"],"prefix":"10.1016","volume":"20","author":[{"given":"Sibylle H.","family":"Lob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl J.","family":"Hoban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary R.","family":"Motyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2019.07.017_bib0005","doi-asserted-by":"crossref","first-page":"212527","DOI":"10.7573\/dic.212527","article-title":"How to manage Pseudomonas aeruginosa infections","volume":"7","author":"Bassetti","year":"2018","journal-title":"Drugs Context"},{"issue":"2","key":"10.1016\/j.jgar.2019.07.017_bib0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.chest.2016.03.042","article-title":"Community-acquired pneumonia due to multidrug- and non-multidrug-resistant Pseudomonas aeruginosa","volume":"150","author":"Cill\u00f3niz","year":"2016","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.jgar.2019.07.017_bib0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.bjid.2017.03.006","article-title":"Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013\u20132015","volume":"21","author":"Karlowsky","year":"2017","journal-title":"Braz J Infect Dis"},{"issue":"6","key":"10.1016\/j.jgar.2019.07.017_bib0020","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.clinthera.2016.04.035","article-title":"Pathogen prevalence and antimicrobial susceptibility among Enterobacteriaceae causing hospital-associated intra-abdominal infections in adults in the United States (2012\u20132013)","volume":"38","author":"Zalacain","year":"2016","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.jgar.2019.07.017_bib0025","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jac\/dkx009","article-title":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012\u201315)","volume":"72","author":"Pfaller","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jgar.2019.07.017_bib0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jgar.2019.07.017_bib0035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijantimicag.2015.02.022","article-title":"Ceftazidime\/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia","volume":"46","author":"Sader","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2019.07.017_bib0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jgar.2018.05.017","article-title":"Activity of imipenem\/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015\u20132016","volume":"15","author":"Lob","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"issue":"3","key":"10.1016\/j.jgar.2019.07.017_bib0045","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.diagmicrobio.2010.10.027","article-title":"Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada \u2013 results of the CANWARD 2007\u20132009 study","volume":"69","author":"Lagac\u00e9-Wiens","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.jgar.2019.07.017_bib0050","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.diagmicrobio.2016.04.022","article-title":"Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010\u20132014","volume":"85","author":"Lob","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.jgar.2019.07.017_bib0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.diagmicrobio.2017.06.009","article-title":"Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: prevalence and risk factors","volume":"89","author":"Trinh","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2019.07.017_bib0060","unstructured":"National Institutes of Health. U.S. National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov. Retrieved from https:\/\/clinicaltrials.gov [accessed 01.15.18]."},{"issue":"8","key":"10.1016\/j.jgar.2019.07.017_bib0065","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and \u2018problem\u2019 Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.07.017_bib0070","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"Clinical and Laboratory Standards Institute","year":"2018"},{"key":"10.1016\/j.jgar.2019.07.017_bib0075","series-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2018"},{"issue":"6","key":"10.1016\/j.jgar.2019.07.017_bib0080","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane\u2013tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jgar.2019.07.017_bib0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2018.04.012","volume":"92","author":"Sader","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl_1","key":"10.1016\/j.jgar.2019.07.017_bib0090","doi-asserted-by":"crossref","first-page":"i31","DOI":"10.1093\/jac\/dkt024","article-title":"Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals","volume":"68","author":"Adam","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jgar.2019.07.017_bib0095","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13054-015-0926-5","article-title":"An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance","volume":"19","author":"Micek","year":"2015","journal-title":"Crit Care"},{"issue":"7","key":"10.1016\/j.jgar.2019.07.017_bib0100","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00465-17","article-title":"Ceftolozane\u2013tazobactam activity against Pseudomonas aeruginosa clinical isolates from U.S. hospitals: report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015","volume":"61","author":"Shortridge","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519301833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519301833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:55:46Z","timestamp":1761990946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716519301833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":20,"alternative-id":["S2213716519301833"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2019.07.017","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of ceftolozane\u2013tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata \u2013 SMART United States 2016\u20132017","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2019.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}